Platelet function in ischemic heart disease.

Area of Science:

• Cardiovascular Medicine
• Hematology
• Pharmacology

Background:

• Blood platelets (PLTs) are central to atherothrombosis and thrombus formation following atherosclerotic plaque rupture.
• Anti-PLT therapy is standard for patients undergoing cardiopulmonary bypass grafting.
• Platelets interact with vascular cells, contributing to inflammation and fibroproliferation, impacting outcomes.

Purpose of the Study:

• To review the established role of platelets in hemostasis and atherothrombosis.
• To summarize the current landscape of anti-platelet (anti-PLT) therapies.
• To highlight novel anti-PLT agents for cardiovascular event prevention.

Main Methods:

• Literature review of clinical trials and existing research on anti-PLT therapy.
• Analysis of platelet interactions in vascular inflammation and fibroproliferation.
• Evaluation of current and emerging anti-PLT drug efficacy and limitations.

Main Results:

• Platelet function blockade is effective in preventing acute coronary syndromes.
• Platelet inhibition is widely used in cardiopulmonary bypass grafting.
• Variability in response to anti-PLT drugs can lead to adverse outcomes and increased interventions.

Conclusions:

• Platelets are critical in cardiovascular pathophysiology, necessitating effective anti-PLT strategies.
• Current anti-PLT therapies offer benefits but face challenges like response variability.
• New anti-PLT drugs show promise in improving prevention of serious cardiovascular events.